Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 878 Results

Intervention Indication Therapeutic Area Year Actions
Tofacitinib for polyarticular juvenile idiopathic arthritis Tofacitinib citrate (Xeljanz; CP-690550) Juvenile idiopathic arthritis Rheumatology 2019 View  |  Download
Tofersen for the treatment of amyotrophic lateral sclerosis caused by mutations in the SOD1 gene Tofersen sodium (BIIB067) Motor neurone disease (MND or ALS) Neurology 2020 View  |  Download
Tonogenchoncel-L (Invossa) Gene Therapy for Regeneration of Cartilage in Patients with Degenerative Arthritis or Osteoarthritis of the Knee Tonogenchoncel-L (Invossa; TG-C) Regeneration of cartilage Musculoskeletal System 2017 View  |  Download
Topical sirolimus for angiofibroma in tuberous sclerosis complex Sirolimus (Rapamune; NPC-12G; Opsiria; DE-109) Tuberous sclerosis Genetic Disorders 2021 View  |  Download
Topsalysin for benign prostatic hyperplasia Topsalysin (PRX 302) Benign prostatic hyperplasia (BPH) Men's Health 2017 View  |  Download
Tralesinidase alfa for mucopolysaccharidosis type IIIB (Sanfilippo syndrome type B) Tralesinidase alfa (BMN 250) Mucopolysaccharidosis type IIIB (Sanfilippo B syndrome) Endocrine Nutritional and Metabolic Disorders 2020 View  |  Download
Tralokinumab for adolescents with moderate to severe atopic dermatitis Tralokinumab (CAT-354; LP 0162) Atopic dermatitis Dermatology 2020 View  |  Download
Tralokinumab for atopic dermatitis Tralokinumab (CAT-354; LP 0162) Atopic dermatitis Dermatology 2019 View  |  Download
Tralokinumab for severe, uncontrolled asthma Tralokinumab (CAT-354; LP 0162) Asthma Respiratory System 2017 View  |  Download
Trastuzumab deruxtecan for HER2 mutant unresectable and/or metastatic non-squamous non-small cell lung cancer – second line Trastuzumab deruxtecan (DS-8201a; Enhertu) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2021 View  |  Download
1 2 79 80 81 82 83 87 88
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications